Plasma Cyclophilin A Is a Novel Biomarker for Coronary Artery Disease
Kimio Satoh, MD, PhD; Yoshihiro Fukumoto, MD, PhD; Koichiro Sugimura, MD, PhD; Yutaka Miura, MD, PhD; Tatsuo Aoki, MD, PhD; Kotaro Nochioka, MD, PhD; Shunsuke Tatebe, MD; Saori Miyamichi-Yamamoto, MD, PhD; Toru Shimizu, MD; Shizuka Osaki, BSc; Yusuke Takagi, MD, PhD; Ryuji Tsunayama, MD, PhD; Yoshitaka Ito, MD, PhD; Yasuharu Matsumoto, MD, PhD; Masaharu Nakayama, MD, PhD; Morihiko Takeda, MD, PhD; Jun Takahashi, MD, PhD; Kenta Ito, MD, PhD; Satoshi Yasuda, MD, PhD; Hiroaki Shimokawa, MD, PhD

Background: Oxidative stress induces secretion of cyclophilin A (CyPA) from vascular smooth muscle cells and it plays a crucial role in the pathogenesis of atherosclerosis in mice. Therefore, we tested our hypothesis that plasma CyPA levels are increased in patients with coronary artery diseases (CAD).

Methods and Results: In 320 consecutive patients undergoing coronary angiography, we examined the relationship between plasma CyPA levels and the severity of CAD. We measured plasma CyPA by an immunoassay based on the sandwich technique. Plasma CyPA levels were significantly higher in patients with significant coronary stenosis compared to those without it (P<0.001). A positive correlation was noted between plasma CyPA levels and significant coronary stenosis. The average number of stenotic coronary arteries and the need for coronary intervention were significantly increased in the quartiles of higher CyPA levels (both P<0.001). Indeed, the plasma CyPA level significantly correlated with the presence of CAD (adjusted odds ratio for CAD, 6.20; 95% confidence interval, 3.14–12.27; P<0.001). Interestingly, plasma levels of CyPA increased according to the number of atherosclerotic risk factors, all of which induce oxidative stress. Furthermore, plasma levels of CyPA significantly reduced after medical treatment of risk factors. Finally, CyPA was strongly expressed in coronary atherosclerotic plaque in patients with myocardial infarction.

Conclusions: Plasma CyPA level is a novel biomarker for oxidative stress and CAD in humans. (Circ J 2013; 77: 447–455)

Key Words: Biomarker; Coronary artery disease; Oxidative stress

The development of atherosclerosis is initiated by activation of endothelial cells (EC), leading to expression of adhesion molecules for inflammatory cells. A critical step in the progression of atherosclerosis is the development of an oxidizing environment because of the activation of macrophages that have become loaded with oxidized low-density lipoprotein (LDL) and other lipids. These macrophages produce abundant reactive oxygen species (ROS) and secrete several growth factors that contribute to the progression of atherosclerosis. It has been widely recognized that oxidative stress, generated by excessive ROS, promotes coronary artery diseases (CAD). Moreover, ROS induce the secretion of cyclophilin A (CyPA) from vascular smooth muscle cells (VSMC) and extracellular CyPA induces EC adhesion molecule expression and promotes VSMC proliferation and migration. CyPA is a ubiquitously distributed protein belonging to the immunophilin family, and is recognized as the intracellular receptor for the immunosuppressive drug cyclosporin. CyPA possesses peptidyl-prolyl isomerase activity and plays an important role in protein folding and trafficking of extracellular signal-regulated kinase 1/2 and apoptosis-inducing factor. Although initially CyPA was thought to function primarily as...
an intracellular protein, recent studies have revealed that it can be secreted by cells in response to ROS. Extracellular CyPA is a potent leukocyte chemottractant, and importantly, plasma CyPA is significantly increased in patients with inflammatory diseases such as rheumatoid arthritis. Furthermore, we have found that CyPA expression in mice is closely associated with the development of intimal thickening, aortic aneurysms, and atherosclerosis. The secretion of CyPA is regulated by activation of Rho-kinase, which plays a crucial role in inflammation, vascular contraction, and the development of atherosclerosis. Thus, it seems plausible that the plasma levels of CyPA may discriminate between subjects at high or low risk for CAD.

An ELISA assay for CyPA has recently been developed, enabling measurement of the plasma levels of CyPA. In the present study, we tested our hypothesis that circulating CyPA is detectable in patients with CAD and that these levels are associated with the number of atherosclerosis risk factors, the severity of CAD and the need for future cardiovascular intervention.

Methods

Study Patients
We conducted a prospective observational study of the prognostic value of CyPA in patients with symptoms or signs of CAD who were referred to the Tohoku University Hospital in Sendai for elective coronary angiography (CAG) from November 2007 through October 2011. If patients underwent angiography more than once, our analysis was based only on data obtained at the time of the first angiographic study. Patients with valvular or congenital heart disease were excluded. A total of 320 consecutive patients who had angina pectoris and who were blinded to the patients’ CyPA plasma levels, evaluated the angiograms. Two experienced cardiologists, who were blinded to the patients’ CyPA plasma levels, evaluated the angiograms. The degree of coronary stenosis measured by cineangiography more than once, our analysis was based only on data obtained at the time of the first angiographic study. Patients with valvular or congenital heart disease were excluded.

Coronary Angiography
At baseline, selective CAG was performed with recordings on the angiographic data system. Two experienced cardiologists, who were blinded to the patients’ CyPA plasma levels, evaluated the angiograms. The degree of coronary stenosis was assessed in the direction that showed the most severe stenosis according to the American Heart Association standards. A narrowing of the lumen by more than 50% of the diameter was considered to indicate clinically significant stenosis. The patients were classified according to the severity of CAD as having no clinically significant organic stenosis, or 1-, 2-, or 3-vessel disease. The left anterior descending coronary artery, left circumflex coronary artery, and right coronary artery were examined to evaluate the number of stenotic coronary arteries as 0 to 3-vessel disease. Stenosis of the left main coronary artery was evaluated as 2-vessel disease. The relationship between the plasma CyPA level and the number of stenotic coronary arteries was analyzed using the average number of stenotic arteries to assess the severity of CAD.

Immunostaining
We have described the CyPA immunostaining in detail elsewhere. In brief, paraformaldehyde-fixed frozen sections were incubated overnight at 4°C with primary antibody (1:1,000 dilution; Jackson Immuno) and NovaRed substrate kit (SK-4800, Vector Laboratories, Burlingame, CA, USA), were used and counterstained with hematoxylin. As a negative control, species- and isotype-matched IgG were used in place of the primary antibody.

Baseline Measurements
Information on vital status and data were obtained from the department’s database system by means of a computerized search performed on December 7, 2011. No patients were lost to follow-up and all patients had a recorded medical history that included details of any previous MI, previous revascularization, angina pectoris, hypertension, previous stroke or transient ischemic attacks, diabetes, and smoking status. The cardiovascular risk was assessed in terms of hypertension, diabetes, smoking, aging and dyslipidemia. Patients with hypertension were assessed as being at risk if their blood pressure was ≥140/90 mmHg or they had a history of antihypertensive drug use. Patients with diabetes mellitus were assessed as being at risk if their fasting glucose level was ≥126 mg/dl or they had a history of hypoglycemic drug or insulin use. Patients with dyslipidemia were assessed as being at risk if their LDL cholesterol was ≥140 mg/dl or their high-density lipoprotein cholesterol was ≤40 mg/dl, or they were taking a lipid-lowering drug. Before CAG, fasting blood samples for the measurement of CyPA were drawn from the antecubital vein of the patients who were resting supine. Plasma samples were collected using EDTA and centrifuged for 10 min at 2,500 g within 30 min of collection, and aliquots were stored at −80°C. CyPA was measured with use of an immunoassay based on the sandwich technique according to the protocol (Human Cyclophilin A ELISA Kit, CSB-E09920h, Cusabio). The detection limit was 0.78 ng/ml. Across the entire analysis, duplicate measures of plasma CyPA level were highly correlated (r=0.92, Figure S1A). The values of high-sensitivity CRP (hsCRP) were measured with a sandwich technique (Roche Diagnostics). The values of other laboratory parameters were obtained from samples assayed in an autoanalyzer in the hospital.

Statistical Analysis
Baseline characteristics of the study patients, grouped according to quartiles of CyPA, are presented as frequencies and percentages, and continuous variables as means and standard deviations, or medians and interquartile ranges for variables with skewed distributions. Baseline characteristics were compared among quartiles with use of the chi square test for discrete variables and the Wilcoxon or Kruskal-Wallis rank-sum test for continuous variables when appropriate.

Additional CyPA analyses were performed in subgroups defined according to the results of angiography. A Student’s t-test was used for comparisons between 2 groups and Dunnett’s multiple comparison of means was used for multi-group comparison after analysis of variance (ANOVA). Receiver-operating-characteristic (ROC) curves were constructed to assess the sensitivity and specificity of plasma CyPA measurements obtained before CAG and to compare the ability to diagnose the existence and severity of CAD.

Logistic regression was used to estimate the association between plasma CyPA levels and CAD status after adjustment for age, sex, smoking status, presence or absence of diabetes, presence or absence of hypertension, and LDL cholesterol level. hsCRP levels were added in subsequent models. Adjusted odds ratios (ORs) are reported both for plasma CyPA levels >15 ng/ml and across quartiles. Model performance was as-

Circulation Journal Vol.77, February 2013
Cyclophilin A and CAD

Assessed according to discrimination, by means of the area under the ROC (c-statistic); calibration, as indicated by the Hosmer-Lemeshow goodness-of-fit statistic. Analyses were performed with CyPA as a categorical variable with the lowest quartile serving as reference for the other 3 quartiles. All reported P values are 2-tailed, with P<0.05 indicating statistical significance. Analyses were performed with SPSS, version 19.0 (Chicago, IL, USA) and JMP, version 9.02 (Cary, NC, USA).

Results

Plasma Levels of CyPA and Angiographic Status

Figure 1A shows the distribution of patients with and without coronary artery stenosis by the plasma level of CyPA. The plasma levels of CyPA were significantly higher in patients with coronary organic stenosis compared with those without stenosis (Figure 1B). Moreover, the CyPA level increased with the severity of angiographic CAD (P<0.001, Figure 1C).

All the cases were divided into quartile groups based on the plasma level of CyPA to examine its correlation with the number of stenotic coronary arteries. Table 1 shows the patients’ clinical background and laboratory data according to the quartiles of CyPA. Patients with CyPA in the upper quartile were older and were more likely to have clinically significant CAD (P<0.001, Table 1). The prevalence of both hypertension and diabetes was higher in the 4th quartile, and these patients showed a slightly reduced estimated glomerular filtration rate (eGFR). The number of stenotic coronary arteries was significantly increased in the higher quartiles of CyPA (P<0.001, Figure 2A). Furthermore, the requirement for cardiovascular intervention, such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), was significantly increased in the 4th quartile compared with the lower quartiles (P<0.001, Figure 2B). We calculated the ROC curves and c-statistic on the basis of the plasma CyPA levels. The ROC curves demonstrated that the plasma level of CyPA is useful for the diagnosis of coronary organic stenosis (c-statistic=0.802) and the requirement for cardiovascular intervention (c-statistic=0.793) (Figures 2C,D).

Plasma Levels of CyPA and the Severity of CAD

CyPA was elevated in patients with traditional cardiovascular risk factors such as hypertension, diabetes, smoking, dyslipidemia and advanced age (all P<0.001, Figure 3). Division of the cohort into quartiles according to plasma CyPA level provided additional evidence of an association between plasma
CyPA and CAD (Table 2). In the analysis adjusted for age, sex, and traditional cardiovascular risk factors (smoking, diabetes, hypertension, dyslipidemia), quartiles 2, 3, and 4 of plasma CyPA were associated with an increased risk of CAD as compared with the quartile of lowest CyPA (OR, 1.73, 9.94, and 10.29; P-value for trend <0.001). This result remained significant after adjustment for traditional cardiovascular risk factors plus hsCRP levels (OR, 1.84, 10.53, and 10.78; P-value for trend <0.001). Several known cardiovascular risk factors were associated with CAD in logistic-regression models adjusted for age, sex, and body mass index (BMI) (Figure 4). Diabetes and hypertension were each linked to an increased risk of CAD. Each of the known risk factors, in addition to plasma CyPA, was combined in a single logistic-regression analysis (Figure 4). In this model, which included the hsCRP level, plasma CyPA >15 ng/ml remained highly related with disease status (OR 6.20, P<0.001). Multivariable analysis demonstrated that, in addition to the established risk factors (age, sex, smoking, hypertension, diabetes and hsCRP), CyPA >15 ng/ml was significantly correlated with CAD (Table 3).

The inclusion of plasma CyPA resulted in significant improvement of the overall performance of the logistic-regression model. The c-statistic increased from 0.807 to 0.870 when plasma CyPA was added to known cardiovascular risk factors (age, sex, smoking, hypertension, diabetes, dyslipidemia). When the hsCRP level was included in the baseline model, the c-statistic increased from 0.807 to 0.873. The addition of plasma CyPA did not reduce model discrimination as assessed by goodness-of-fit statistics. CyPA added prognostic information above and beyond that provided by age, sex, family history

Table 1. Baseline Clinical Characteristics According to Quartiles of CyPA

<table>
<thead>
<tr>
<th></th>
<th>1st quartile (n=80)</th>
<th>2nd quartile (n=80)</th>
<th>3rd quartile (n=80)</th>
<th>4th quartile (n=80)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CyPA level (ng/ml)</td>
<td>0.0–6.1</td>
<td>6.2–9.6</td>
<td>9.7–17.4</td>
<td>17.5–50.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>58</td>
<td>63</td>
<td>68</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>Interquartile range</td>
<td>50–68</td>
<td>55–71</td>
<td>60–75</td>
<td>60–74</td>
<td></td>
</tr>
<tr>
<td>Male sex (%)</td>
<td>60</td>
<td>61</td>
<td>66</td>
<td>76</td>
<td>0.122</td>
</tr>
<tr>
<td>Family history of IHD (%)</td>
<td>11</td>
<td>18</td>
<td>4</td>
<td>10</td>
<td>0.046</td>
</tr>
<tr>
<td>Medical history (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>56</td>
<td>59</td>
<td>75</td>
<td>88</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>36</td>
<td>34</td>
<td>48</td>
<td>55</td>
<td>0.022</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>51</td>
<td>51</td>
<td>70</td>
<td>80</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Current smoker (%)</td>
<td>28</td>
<td>34</td>
<td>49</td>
<td>59</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Angiographic findings (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No coronary artery stenosis</td>
<td>71</td>
<td>61</td>
<td>20</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>1-vessel disease</td>
<td>23</td>
<td>31</td>
<td>41</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>2-vessel disease</td>
<td>3</td>
<td>4</td>
<td>24</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>3-vessel disease</td>
<td>4</td>
<td>4</td>
<td>11</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Requirement for PCI or CABG during follow-up (%)</td>
<td>8</td>
<td>8</td>
<td>23</td>
<td>40</td>
<td>0.019</td>
</tr>
<tr>
<td>BMI*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.003</td>
</tr>
<tr>
<td>Median</td>
<td>25</td>
<td>24</td>
<td>24</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Interquartile range</td>
<td>23–27</td>
<td>22–26</td>
<td>21–26</td>
<td>21–25</td>
<td></td>
</tr>
<tr>
<td>eGFR (ml·min⁻¹·1.73m⁻²)</td>
<td>54±17</td>
<td>59±19</td>
<td>51±20</td>
<td>49±19</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Left ventricular ejection fraction (%)</td>
<td>65±10</td>
<td>66±8</td>
<td>59±12</td>
<td>63±12</td>
<td>0.090</td>
</tr>
<tr>
<td>Lipid status (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>105±36</td>
<td>105±29</td>
<td>96±35</td>
<td>97±33</td>
<td>0.078</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>47±13</td>
<td>49±12</td>
<td>49±12</td>
<td>49±14</td>
<td>0.837</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>127±69</td>
<td>147±95</td>
<td>130±73</td>
<td>132±100</td>
<td>0.576</td>
</tr>
<tr>
<td>Hemoglobin A₁c</td>
<td>6.4±1.4</td>
<td>6.3±0.8</td>
<td>6.4±0.9</td>
<td>6.6±1.2</td>
<td>0.067</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
<td>2.3±3.2</td>
<td>1.7±2.6</td>
<td>2.3±3.1</td>
<td>1.8±2.8</td>
<td>0.103</td>
</tr>
<tr>
<td>Medication (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>16</td>
<td>30</td>
<td>51</td>
<td>71</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>β-blocker</td>
<td>25</td>
<td>29</td>
<td>46</td>
<td>55</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Statin</td>
<td>39</td>
<td>35</td>
<td>56</td>
<td>70</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ACE inhibitor</td>
<td>28</td>
<td>24</td>
<td>31</td>
<td>39</td>
<td>0.212</td>
</tr>
<tr>
<td>ARB</td>
<td>24</td>
<td>26</td>
<td>28</td>
<td>33</td>
<td>0.654</td>
</tr>
<tr>
<td>Calcium-channel blocker</td>
<td>51</td>
<td>55</td>
<td>61</td>
<td>58</td>
<td>0.550</td>
</tr>
</tbody>
</table>

Data are shown as mean±SD unless otherwise shown.

*BMI=weight in kg/(height in m)²

ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CyPA, cyclophilin A; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IHD, ischemic heart disease; LDL, low-density lipoprotein; PCI, percutaneous coronary intervention.
with respect to ischemic heart disease, presence or absence of hypertension, diabetes, smoking status, BMI, eGFR, and plasma lipid level. Excluding the 141 patients with high hsCRP did not significantly change the results. In patients with hsCRP <1,000, the adjusted OR for CAD in the 4th quartile of CyPA, as compared with the 1st quartile, was 13.2 (95% confidence interval, 3.2–53.9, P<0.001). Additionally, CyPA (>15 ng/ml) remained a strong prognostic marker, with an adjusted OR of 5.9 (95% confidence interval, 2.3–14.8, P<0.001). Among patients with hsCRP >1,000, the same trend was observed, suggesting the potential usefulness of combining these biomarkers for CAD.

**Plasma Levels of CyPA as a Biomarker of Therapeutic Outcome**

Interestingly, the plasma level of CyPA increased according to the atherosclerotic risk factors such as sex, hypertension, diabetes mellitus, dyslipidemia, and smoking, all of which are

---

**Figure 2.** Number of stenotic coronary arteries and requirement for cardiovascular intervention according to quartiles of cyclophilin A (CyPA). Data from 320 patients with and without coronary stenosis are divided according to the quartiles of plasma CyPA levels. The CyPA levels were as follows: 1st quartile (Q1), <6.1 ng/ml; 2nd quartile (Q2), 6.2–9.6 ng/ml; 3rd quartile (Q3), 9.7–17.4 ng/ml; 4th quartile (Q4), >17.5 ng/ml. P<0.001 by the log-rank test for the overall comparison among the groups. (A) Number of stenotic coronary arteries according to quartiles of CyPA. CyPA was elevated in patients in Q3 (P<0.001) and Q4 (P<0.001) compared with Q1. The number of stenotic coronary arteries increased sequentially as the quartiles increased. (B) Requirement for cardiovascular intervention according to quartiles of CyPA. The requirement was higher in patients with Q4 compared with Q1 (P<0.001) and Q2 (P<0.001). Cardiovascular intervention included percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). (C,D) Receiver-operating-characteristic curves (ROC) and c-statistic for baseline measurements of CyPA. Also shown are the sensitivity and specificity of these measures. (C) ROC curve describing the diagnostic performance of CyPA to identify coronary organic stenosis >50% in at least 1 vessel as compared with the reference standard of invasive quantitative coronary angiography (CAG). The c-statistic was 0.80 (95% CI, 0.75–0.85). (D) ROC curve describing the diagnostic performance of CyPA to identify the requirement for future cardiovascular intervention as compared with the reference standard of invasive quantitative CAG. The c-statistic was 0.79 (95% CI, 0.74–0.85). CI, confidence interval.
oxidative stress inducers (Figure 3). Therefore, plasma CyPA may be important as a biomarker of therapeutic outcome after controlling risk factors. To further confirm the role of plasma CyPA, we performed a follow-up study after the addition of drugs to control risk factors. After treatment in several individuals (n=42), the plasma obtained at baseline and follow-up (mean follow-up, 273 days) revealed a significant reduction after treatment (P=0.003, Figure 5A). Medical treatments that control atherosclerotic risk factors decreased plasma CyPA levels in patients with stable CAD, suggesting that plasma CyPA is useful for the evaluation of systemic oxidative stress and the therapeutic effect of medication.

**CyPA and Atherosclerotic Unstable Plaque**

As demonstrated, ROS-induced secretory protein CyPA is a useful biomarker of CAD, so we hypothesized that secreted CyPA is highly accumulated in atherosclerotic plaque of coronary arteries. Indeed, we observed strong CyPA expression in coronary arteries in patients with MI (Figures 5B, C). Importantly, the strong expression of CyPA was localized just beneath the thin fibrous cap of atherosclerotic plaque.
Discussion

Our study demonstrated that the plasma level of CyPA in patients with stable CAD provides prognostic information on the severity of CAD and the requirement for cardiovascular intervention. The findings of the present study support our previous results in mice suggesting that CyPA augments the development of atherosclerosis. Patients with high CyPA levels had a significantly higher prevalence of CAD on CAG than those with low levels of CyPA. A possible role for CyPA in atherosclerosis is becoming increasingly apparent. We have shown that knock-down of CyPA in EC reduced apoptosis induced in vitro by tumor-necrosis factor-α and that CyPA deficiency was associated with a marked decrease in EC apoptosis in the early stages of atherosclerosis. The increase in vascular oxidative stress requires CyPA which thereby sensitizes EC to apoptosis. In addition, CyPA secretion is regulated by Rho-kinase activation, which is important for VSMC contraction and atherosclerosis. Consistently, plasma levels of CyPA were significantly increased in patients with CAD.

In the present study, plasma levels of CyPA were elevated in patients with angiographically verified coronary atherosclerosis. We have previously demonstrated that ROS inducers, such as mechanical stress, angiotensin II and dyslipidemia, promote the secretion of CyPA in a Rho-kinase-dependent manner. It is well known that Rho-kinase is associated with activation of the NADPH oxidases, with resultant ROS production, which plays a crucial role in the development of several cardiovascular diseases. In support of this notion, CyPA was elevated in patients with hypertension, diabetes, smoking, dyslipidemia, and advanced age in the present study. This is the first study that has examined the association between CyPA and ROS inducers, all of which are atherosclerotic risk factors in humans.

Plasma CyPA and Atherosclerotic Risk Factors

In the present study, we further examined the prognostic importance of CyPA in patients with stable CAD. We found that CyPA is a prognostic marker for requirement of cardiovascular intervention such as PCI and CABG. The increased severity of CAD we observed among patients with elevated CyPA may be a consequence of a higher frequency of risk factors for atherosclerosis, all of which promote ROS production and CyPA secretion. All these mechanisms, while promoting an environment of oxidative stress, are likely to contribute to the increased plasma levels of CyPA in patients with severe CAD. Vascular ROS formation can be stimulated by mechanical stretch, pressure, shear stress, environmental factors such as hypoxia, and secreted factors such as angiotensin II. In addition, extracellular CyPA induces ROS production in VSMC.
and recruitment of inflammatory cells, resulting in augmentation of vascular ROS and atherosclerosis. All these data comprise a proof-of-concept that circulating CyPA is a novel biomarker for CAD and also plays a crucial role in ROS augmentation. Several risk factors, such as hypertension, diabetes, smoking and aging, induce the generation of ROS and promote the secretion of CyPA. Circulating CyPA augments ROS production synergistically. Therefore, secreted plasma CyPA, acting as a pro-inflammatory cytokine, synergistically augments ROS production, contributing to the onset of atherosclerosis and its progression.

**CyPA and Atherosclerotic Unstable Plaque**

CyPA may play an important role in several stages of atherosclerosis. During fatty streak formation, it may play a role in lipid uptake via its effect on scavenger receptors. In all stages, it may play a role in inflammation by promoting monocyte adhesion and recruitment, as well as by contributing to an oxidative environment. The data from Seizer et al that CyPA is secreted from foam cells suggest an important role in the later stages of atherosclerosis. Indeed, we observed strong CyPA expression in the atherosclerotic plaque of patients with MI. Altogether, our data suggest that the agents that inhibit CyPA secretion might be candidates for suppressing the development of atherosclerosis. EMMPRIN, a putative CyPA receptor, has been identified as a tumor cell membrane protein that is expressed in VSMC, is activated by ROS and stimulates matrix metalloproteinase production. A recent study demonstrated ROS-dependent increases in EMMPRIN, which may be activated by the binding of extracellular CyPA. Therefore, ROS-induced secretion of CyPA may also contribute to the development of unstable atherosclerotic plaque and plaque rupture. We consider that the discovery of more selective and specific inhibitors of CyPA secretion may be an effective therapeutic approach for CAD.

**Study Limitations**

Several limitations should be mentioned. First, the study population was relatively small. However, even in this small population, plasma levels of CyPA closely related with the severity of CAD. Future analysis in a large population prospective cohort will further elucidate the importance of plasma CyPA in CAD. Second, as to the plasma levels of CyPA in patients with MI, we need to consider 2 different mechanisms that increase the plasma level of CyPA. One mechanism is oxidative stress-induced CyPA secretion from the vasculature and another is CyPA release from necrotic tissue after MI. Therefore, in the present study, we excluded patients with unstable CAD or MI and recruited patients with stable CAD. The plasma levels in patients with unstable CAD or MI need to be examined in future studies.

In conclusion, the present study indicates that the plasma CyPA level is a novel biomarker of CAD. Further studies are needed to further establish the clinical significance of CyPA in the pathogenesis of atherosclerotic cardiovascular disease.

**Acknowledgments**

This work was supported in part by a Grant-in-Aid for Scientific Research on Innovative Areas (Signaling Functions of Reactive Oxygen Species) (08107961), a Grant-in-Aid for Tohoku University Global COE for Conquest of Signal Transduction Diseases with Network Medicine, and Grants-in-Aid for Scientific Research (08101562, 09006924 and 10002019), all of which are from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan, and the Grants-in-Aid for Scientific Research from the Ministry of Health, Labour, and Welfare, Tokyo, Japan (10102895),

![Figure 5](image-url).

**Figure 5.** Plasma levels of cyclophilin A (CyPA) after treatment and representative immunostaining for CyPA in atherosclerotic coronary plaque from a patient with acute myocardial infarction. (A) Plasma levels of CyPA at baseline and follow-up (n=42, mean follow-up, 273 days). (B, C) Coronary artery sample obtained from a patient with acute myocardial infarction showing strong CyPA expression just beneath the thin fibrous cap of atherosclerotic plaque. Bars=500 μm.
Disclosures
Conflict of Interest: None declared.

References


